Stock price when the opinion was issued
(Past Top Pick May 4, 2018, Down 2%) It pulled back heavily after August earnings. There were concerns over legacy products lines and weak organic growth. He used that pullback to double his position. Still likes it. There's margin expansion as they consolidate their manufacturing operation. They have high-growth product lines with EPS growth at 15%. He really likes the medical products space because of the aging population.